These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses. Zhu F; Ramadan G; Davies B; Margolis DA; Keever-Taylor CA Clin Exp Immunol; 2008 Feb; 151(2):284-96. PubMed ID: 18005260 [TBL] [Abstract][Full Text] [Related]
5. Induction of minor histocompatibility antigen-specific T-helper but not T-cytotoxic response is dependent on the source of antigen-presenting cell. van Els CA; Bakker A; van Rood JJ; Goulmy E Hum Immunol; 1990 May; 28(1):39-50. PubMed ID: 2160446 [TBL] [Abstract][Full Text] [Related]
6. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Heiser A; Maurice MA; Yancey DR; Coleman DM; Dahm P; Vieweg J Cancer Res; 2001 Apr; 61(8):3388-93. PubMed ID: 11309297 [TBL] [Abstract][Full Text] [Related]
7. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Bollard CM; Gottschalk S; Leen AM; Weiss H; Straathof KC; Carrum G; Khalil M; Wu MF; Huls MH; Chang CC; Gresik MV; Gee AP; Brenner MK; Rooney CM; Heslop HE Blood; 2007 Oct; 110(8):2838-45. PubMed ID: 17609424 [TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes. Ramadan G Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679 [TBL] [Abstract][Full Text] [Related]
9. Presentation of Candida albicans and purified protein derivative soluble antigens by Epstein-Barr virus-transformed human lymphoblastoid B-cell lines. Reitnauer PJ; Brown LR; Hank JA; Sondel PM Cell Immunol; 1986 Apr; 99(1):196-208. PubMed ID: 3019572 [TBL] [Abstract][Full Text] [Related]
10. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes. Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087 [TBL] [Abstract][Full Text] [Related]
11. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505 [TBL] [Abstract][Full Text] [Related]
12. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031 [TBL] [Abstract][Full Text] [Related]
13. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498 [TBL] [Abstract][Full Text] [Related]
14. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Mutis T; Schrama E; Melief CJ; Goulmy E Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596 [TBL] [Abstract][Full Text] [Related]
15. Use of Epstein-Barr virus-transformed, autologous B-lymphoblastoid cells as antigen-presenting cells for establishment and maintenance of dengue virus-specific, human cytotoxic T lymphocyte clones. Livingston PG; Kurane I; Ennis FA J Virol Methods; 1997 Aug; 67(1):77-84. PubMed ID: 9274820 [TBL] [Abstract][Full Text] [Related]
16. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. Long HM; Zuo J; Leese AM; Gudgeon NH; Jia H; Taylor GS; Rickinson AB Blood; 2009 Jul; 114(4):807-15. PubMed ID: 19443664 [TBL] [Abstract][Full Text] [Related]
17. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab. Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B Front Immunol; 2023; 14():878953. PubMed ID: 37033971 [TBL] [Abstract][Full Text] [Related]
18. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597 [TBL] [Abstract][Full Text] [Related]
19. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926 [TBL] [Abstract][Full Text] [Related]
20. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Herr W; Ranieri E; Olson W; Zarour H; Gesualdo L; Storkus WJ Blood; 2000 Sep; 96(5):1857-64. PubMed ID: 10961887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]